PPT-Canadian Cardiovascular

Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease Disclaimer The Canadian Cardiovascular Society CCS welcomes reuse of our educational slide deck for medical institution internal education or training ie grand rounds medical collegeclassroom education etc  However if the material is being used in an industry sponsored CME program permission must be sought through our publisher Elsevier . Antiplatelet Guidelines. PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY. Working Group: . James D. Douketis MD, FRCP(C); A. Graham . Turpie. MD, FRCP(C). Objectives. Interpret the Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. By: Jeremy Clark, Megan Windland, and Tiana Nater. Negative Effects of Cardiovascular disease. Eating foods that are high in saturated fats and cholesterol may cause plaque to form on artery walls. . Antiplatelet. Guidelines. INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS. Working Group. : Wee Shian Chan, MD, FRCP; Alan D. Bell, MD, CCFP. Objectives. Interpret the . Canadian Cardiovascular Society . ASA – NSAID Drug/Drug Interaction. Working Group: . Alan D. Bell, MD, CCFP; Wee . Shian. Chan, MD, FRCP. Objectives. Interpret. . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet therapy in patients . CarTarDis. = . Car. diovascular . Tar. get . Dis. covery. Public-private partnership. 13 partners, 8 countries, project budget 8.0M Eur. Start 1 Oct 2013 for 4 years. (Coordinator). CarTarDis. ASA – NSAID Drug/Drug Interaction. Working Group: . Alan D. Bell, MD, CCFP; Wee . Shian. Chan, MD, FRCP. Objectives. Interpret. . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet therapy in patients . October 2018. Endorsed by the Canadian Association . of Emergency Physicians (CAEP). 2018 STEMI Guideline Authors. Graham C. Wong MD MPH (Co-Chair), Michelle Welsford MD, Craig Ainsworth MD, Wael Abuzeid MD MSc, Christopher Fordyce MDCM MHS MSc, Jennifer Greene BSc ACP, Thao Huynh MD MSc PhD, Laurie Lambert PhD, Michel Le May MD, Sohrab Lutchmedial MDCM, Shamir Mehta MD MSc, Madhu Natarajan MD MSc, Colleen Norris RN, MN, PhD, Christopher Overgaard MD MSc, Michele Perry . Toni . Mustahsani. . Aprami. , dr., . Sp.PD. , Sp.JP. Department of Cardiology and Vascular Medicine. Cardiovascular Subdivision, Department of Internal Medicine. Hasan. . Sadikin. Hospital/Medical School, . CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. www.onlinecjc.com. ).  . If your reuse request qualifies as medical institution internal education, you may reuse the material under the following conditions:. You . must cite the Canadian Journal of Cardiology and the Canadian . The Heart. The Heart. The Heart. A fist-sized, cone-shaped muscle (the myocardium) that beats, on average, 80 times per minute . . Divided into right and left sides by a muscular wall, the septum . . Diseases of the Cardiovascular System. 20.3 Cardiovascular and Lymphatic System Diseases Caused by Microorganisms. A. Endocarditis . 1. Inflammation of the endocardium . 2. Usually refers to an infection of the valves of the heart. A Scientific Statement From the AHA. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM). A systemic disorder characterized by pathophysiologic interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multi-organ dysfunction and a high rate of adverse cardiovascular outcomes..